Real-life Experience: Early Recurrence with Hexvix Photodynamic Diagnosis-assisted Transurethral Resection of Bladder Tumour vs Good-quality White Light TURBT in New Non-muscle-invasive Bladder Cancer

Urology

Volumn 86, Issue 2, 2015, Pages 327-331

  Mariappan, Paramananthan ^a   Rai, Bhavan ^a   El Mokadem, Ismail ^a   Anderson, Claire H ^a   Lee, Hannah ^a   Stewart, Sarah ^a   Donat, Roland ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; MITOMYCIN;

AGED; ARTICLE; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; CYSTOSCOPY; FOLLOW UP; GOOD QUALITY WHITE LIGHT TRANSURETHRAL RESECTION OF BLADDER TUMOR; HUMAN; INTERMEDIATE RISK PATIENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NON MUSCLE INVASIVE BLADDER CANCER; PERSONAL EXPERIENCE; PHOTODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF BLADDER TUMOR; WHITE LIGHT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CYSTECTOMY; DIAGNOSTIC USE; LIGHT; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; TIME; TUMOR INVASION; URETHRA; URINARY BLADDER NEOPLASMS;

CYSTECTOMY; HUMANS; LIGHT; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TIME FACTORS; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84939771400     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2015.04.015     Document Type: Article

References (23)

1. P. Mariappan, A. Zachou, and K.M. Grigor Detrusor Muscle in the first, apparently complete TURBT specimen is a surrogate marker of resection quality, predicts risk of early recurrence and is dependent on operator experience Euro Urol 57 2009 843 849
2. P. Mariappan, S. Finney, E. Head, and et al. Good quality white light resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces recurrence in new NMIBC - validation across time and place and recommendation for benchmarking BJU Int 109 2012 1666 1673
3. M.A. Brausi, M. Gavioli, G. Peracchia, and et al. Dedicated teaching programs can improve the quality of TUR of non-muscle-invasive bladder tumours (NMIBT): experience of a single institution Eur Urol Suppl 7 2008 180
4. D. Jocham, F. Witjes, S. Wagner, and et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicentre study J Urol 174 2005 862 866
5. C.R. Riedl, D. Daniltchenko, F. Koenig, and et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer J Urol 165 2001 1121 1123
6. Scottish Intercollegiate Guidelines Network: SIGN 85. Available at: http://sign.ac.uk/pdf/sign85.pdf. Accessed November 16, 2014.
7. A. Stenzl, M. Burger, Y. Fradet, and et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer J Urol 184 2010 1907 1913
8. H.B. Grossman, L. Gomella, Y. Fradet, and et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer J Urol 178 2007 62 67
9. M. Burger, H.B. Grossman, M. Droller, and et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data Eur Urol 64 2013 846 854
10. M. Rothwell Peter External validity of randomised trials: "to whom do the results of this trial apply?" Lancet 365 2005 82 93
11. R.M. Sanson-Fisher, B. Bonevski, L.W. Green, and C. D'Este Limitations of the randomized controlled trial in evaluating population-based health interventions Am J preventative Med 33 2007 155 161
12. K. Stanley Evaluation of randomized controlled trials Circulation 115 2007 1819 1822
13. C.H. Anderson, H. Lee, B.P. Rai, and et al. RRFFC following PDD-TURBT is better than even GQ-WLTURBT - a prospective controlled study BJUI 108 Suppl 1 2010 6
14. A. Lapini, A. Minervini, A. Masala, and et al. A comparison of hexaminolevulinate (Hexvix®) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study Surg Endosc 26 2012 3634 3641
15. H.W. Herr Surgical factors in the treatment of superficial and invasive bladder cancer Urol Clin North Am 32 2005 157 164
16. Jancke G, Rosell J, Jahnson S. Impact of surgical experience on recurrence and progression after traunsurethral resection of bladder tumour in NMIBC, 2013. http://dx.doi.org/10.3109/21681805.2013.864327.
17. P. Mariappan, G. Smith, A.D. Lamb, and et al. Pattern of recurrence changes in noninvasive bladder tumours observed during 2 decades J Urol 177 2007 867 875
18. European Association of Urology M. Babjuk, M. Burger, R. Zigeuner, and et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013 Eur Urol 64 2013 639 653
19. M. Kriegmair, D. Zaak, A.G. Hofstetter, and et al. Transurethral resection of bladder cancer controlled by 5-aminolevulinic acid induced fluorescence endoscopy (AFE) versus white light endoscopy J Urol Suppl 163 2000 149 abstract 664
20. H.W. Herr The value of a second transurethral resection in evaluating patients with bladder tumours J Urol 162 1999 74 76
21. A. Brauers, R. Büttner, and G. Jakse 2nd Resection and prognosis in primary high risk superficial bladder cancer J Urol 165 2001 808 810
22. H. Schwaibold, U. Treiber, H. Kübler, and et al. Significance of 2nd transurethral resection for T1 bladder cancer Eur Urol 37 Suppl 2 2000 11
23. M. Burger, D. Zaak, C.G. Stief, and et al. Photodynamic diagnostics and noninvasive bladder cancer: Is it cost effective in long-term application? A German-based cost analysis Eur Urol 52 2007 142 147